Print

MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.) to Host Investor Update Conference Call  
7/19/2013 9:56:48 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, CA--(Marketwired - July 19, 2013) - Medistem, Inc. (PINKSHEETS: MEDS) today announced that Alan J. Lewis, Ph.D., the Company's Chief Executive Officer, will host a conference call at 4:30 pm Eastern time (1:30 pm Pacific time) on July 25, 2013. Dr. Lewis will provide a business update and discuss the Company's plans. Investors may participate either by phone or audio webcast.

By Phone:

Dial (877) 407-8033 at least 10 minutes before the call. A replay will be available through August 2, 2013 by dialing (201) 612-7415 and using the access code 418178#.

By Audio Webcast:

Visit http://www.investorcalendar.com/IC/CEPage.asp?ID=171350. Please log in at least 10 minutes in advance to register and download any necessary software. A replay will be available shortly after the call.

About Medistem, Inc.

Medistem, Inc., is developing ERC-124, a universal stem cell product derived from the endometrium. ERC-124 possesses specialized abilities to stimulate new blood vessel formation and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERC-124 has been cleared by the FDA to begin a CLI clinical trial in the United States. In January 2012, the Company announced the initiation of its RECOVER-ERC (Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy) a double blind, placebo controlled, clinical trial. This trial is being conducted at the Bakulev Scientific Center for Cardiovascular Surgery, Moscow, Russia. The trial is a 60 patient double blind placebo controlled study evaluating safety and efficacy of ERC-124 in end stage CHF patients.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Medistem, Inc. These can be identified by the use of forward-looking words, such as "believes", "expects", "may", "intends", "anticipates", "plans", "estimates", or any other analogous or similar expressions intended to identify forward-looking statements. These forward-looking statements and estimates as to future performance, estimates, and other statements contained herein regarding matters that are not historical facts, are only predictions and actual events or results may differ materially. We cannot assure or guarantee that any future results described in this presentation will be achieved, and actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


Contact:

John P. Salvador
626.644.6092
john.salvador@medisteminc.com



Help employers find you! Check out all the jobs and post your resume.

//-->